» Articles » PMID: 21543485

An HIV-1 Gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum

Abstract

Among nonneutralizing HIV-1 envelope antibodies (Abs), those capable of mediating antibody-dependent cellular cytotoxicity (ADCC) activity have been postulated to be important for control of HIV-1 infection. ADCC-mediating Ab must recognize HIV-1 antigens expressed on the membrane of infected cells and bind the Fcγ receptor (FcR) of the effector cell population. However, the precise targets of serum ADCC antibody are poorly characterized. The human monoclonal antibody (MAb) A32 is a nonneutralizing antibody isolated from an HIV-1 chronically infected person. We investigated the ability of MAb A32 to recognize HIV-1 envelope expressed on the surface of CD4(+) T cells infected with primary and laboratory-adapted strains of HIV-1, as well as its ability to mediate ADCC activity. The MAb A32 epitope was expressed on the surface of HIV-1-infected CD4(+) T cells earlier than the CD4-inducible (CD4i) epitope bound by MAb 17b and the gp120 carbohydrate epitope bound by MAb 2G12. Importantly, MAb A32 was a potent mediator of ADCC activity. Finally, an A32 Fab fragment blocked the majority of ADCC-mediating Ab activity in plasma of subjects chronically infected with HIV-1. These data demonstrate that the epitope defined by MAb A32 is a major target on gp120 for plasma ADCC activity.

Citing Articles

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption.

Sanchez-Gaona N, Perea D, Curran A, Burgos J, Navarro J, Suanzes P Commun Biol. 2025; 8(1):236.

PMID: 39953264 PMC: 11829058. DOI: 10.1038/s42003-025-07651-6.


FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.

Weeden T, Picariello T, Quinn B, Spring S, Shen P, Qiu Q Commun Med (Lond). 2025; 5(1):22.

PMID: 39827287 PMC: 11742727. DOI: 10.1038/s43856-025-00733-w.


CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies.

Richard J, Sannier G, Zhu L, Prevost J, Marchitto L, Benlarbi M mBio. 2024; 15(11):e0182724.

PMID: 39373535 PMC: 11559134. DOI: 10.1128/mbio.01827-24.


Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing.

de Taeye S, Schriek A, Umotoy J, Grobben M, Burger J, Sanders R Commun Biol. 2024; 7(1):964.

PMID: 39122901 PMC: 11316088. DOI: 10.1038/s42003-024-06659-8.


Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.

Kaur A, Vaccari M Viruses. 2024; 16(3).

PMID: 38543734 PMC: 10974975. DOI: 10.3390/v16030368.


References
1.
Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N . Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996; 70(2):1100-8. PMC: 189917. DOI: 10.1128/JVI.70.2.1100-1108.1996. View

2.
Tyler D, Stanley S, Zolla-Pazner S, Gorny M, Shadduck P, Langlois A . Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol. 1990; 145(10):3276-82. View

3.
Stratov I, Chung A, Kent S . Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol. 2008; 82(11):5450-9. PMC: 2395196. DOI: 10.1128/JVI.01952-07. View

4.
Gomez-Roman V, Patterson L, Venzon D, Liewehr D, Aldrich K, Florese R . Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol. 2005; 174(4):2185-9. DOI: 10.4049/jimmunol.174.4.2185. View

5.
Adachi A, Gendelman H, Koenig S, Folks T, Willey R, Rabson A . Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59(2):284-91. PMC: 253077. DOI: 10.1128/JVI.59.2.284-291.1986. View